Antagonists of IL-6 to raise albumin and/or lower CRP
US8404235B2 · kind B2 · utility
29Cited by
65References
29Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 25, 2008 |
| Grant date | Mar 26, 2013 |
| Priority date | — |
| Expiry date | Nov 25, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.